A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-17

Study Completion Date

2025-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to evaluate the safety and tolerability of H021 tablets following oral administration of single and multiple ascending doses in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HMPL004-6599 Phase I Dose-escalating Study

NCT03597971

Ulcerative Colitis Crohn Disease

TERMINATED PHASE1

Phase II Study of HMPL-004 in Patients With Ulcerative Colitis

NCT00659802

Ulcerative Colitis

COMPLETED PHASE2

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

NCT05088369

Ulcerative Colitis Crohn's Disease

COMPLETED PHASE1

First in Human, Single Ascending Dose Study

NCT05844592

Ulcerative Colitis

COMPLETED PHASE1

A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis

NCT04457960

Healthy Colitis, Ulcerative

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single center, Phase 1, randomized, double-blind, placebo controlled, sequential single ascending dose/multiple ascending dose (SAD/MAD) study, with a food-effect arm. The study will be divided into two parts:

* SAD cohorts, with food-effect evaluation
* MAD cohorts The two parts will be completed sequentially but with partial overlapping. The MAD phase can start once safety, tolerability, and pharmacokinetic data from the SAD phase show that single doses of at least 25 mg are acceptable. If the 25 mg dose will be not reached in the SAD phase, the Safety Review Committee (SRC) will set a new starting dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAD Cohort 1: H021 6.25 milligrams (mg)

Participants will receive H021, 6.25 mg oral tablet, as single-dose on Day 1 under fasting or fed conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

SAD Cohort 2: H021 12.5 mg

Participants will receive H021, 12.5 mg oral tablet, as single-dose on Day 1 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

SAD Cohort 3: H021 25 mg

Participants will receive H021, 25 mg oral tablet, as single-dose on Day 1 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

SAD Cohort 4: H021 50 mg

Participants will receive H021, 50 mg oral tablet, as single-dose on Day 1 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

SAD Cohort 5: H021 100 mg

Participants will receive H021, 100 mg oral tablet, as single-dose on Day 1 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

MAD Cohort 6: H021 12.5 mg

Participants will receive H021, 12.5 mg oral tablet once daily from Day 1 to Day 7 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

MAD Cohort 7: H021 25 mg

Participants will receive H021, 25 mg oral tablet once daily from Day 1 to Day 7 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

MAD Cohort 8: H021 50 mg

Participants will receive H021, 50 mg oral tablet once daily from Day 1 to Day 7 under fasting conditions.

Group Type EXPERIMENTAL

H021

Intervention Type DRUG

H021 oral tablet.

SAD-H021 Placebo

Participants will receive H021, placebo oral tablet, as single-dose on Day 1 under fasting or fed conditions.

Group Type PLACEBO_COMPARATOR

H021 Placebo

Intervention Type DRUG

H021 placebo oral tablet.

MAD-H021 Placebo

Participants will receive H021, placebo oral tablet once daily from Day 1 to Day 7 under fasting conditions.

Group Type PLACEBO_COMPARATOR

H021 Placebo

Intervention Type DRUG

H021 placebo oral tablet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

H021

H021 oral tablet.

Intervention Type DRUG

H021 Placebo

H021 placebo oral tablet.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), greater than and equal to (\>=) 18 and less than and equal to (\<=) 55 years of age, with body mass index (BMI) greater than (\>)18.5 and less than (\<) 32.0 kilograms per square meter (kg/m\^2).
2. Healthy as defined by:

1. the absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.
2. the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Female participants of non-childbearing potential must be:

1. post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented follicle-stimulating hormone (FSH) levels \>=40 milli-international units per milliliter (mIU/mL); or
2. surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or bilateral tubal occlusion) at least 3 months prior to dosing.
4. Participants must be willing not to donate sperm for 90 days or ova (egg) for 6 months after the last dose.
5. Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study.
6. Able to understand the study procedures and provide signed informed consent to participate in the study.

Exclusion Criteria

1. Any clinically significant abnormal finding at physical examination.
2. Clinically significant abnormal laboratory test results including biochemistry, hematology, urinalysis, and coagulation results, or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody, or QuantiFERON®-TB test at screening.
3. Positive pregnancy test or lactating female participant.
4. Positive urine drug screen, urine cotinine test, or alcohol breath test at screening or Day -1.
5. History of significant allergic reactions (example, anaphylactic reaction, hypersensitivity, angioedema) to any drug.
6. Clinically significant ECG abnormalities or vital signs abnormalities (systolic blood pressure lower than 90 or over 140 millimetres of mercury (mmHg), diastolic blood pressure lower than 40 or over 90 mmHg, heart rate less than 40 or over 100 beats per minute (bpm), respiratory rate less than 10 or over 22 bpm), or oxygen saturation less than 95 percent (%) oxygen at screening.
7. History of drug abuse within 1 year prior to screening as determined by the investigator.
8. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 1 month prior to screening that exceeds 10 units of alcohol per week for women and men (1 unit = 375 \[milliliter\] mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of distilled alcohol 40%).
9. History of active tuberculosis or presence of active or latent tuberculosis. Previous latent tuberculosis that has been treated and is no longer active is not exclusionary.
10. History of clinically significant opportunistic infection (example, invasive candidiasis or pneumocystis pneumonia).
11. History of serious local infection (example, cellulitis, abscess) or systemic infection (example, septicemia) within 3 months prior to screening.
12. Presence of fever (body temperature greater than (\>) 37.5 degrees Celsius (°C) (example, a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to dosing.
13. Use of medications within the timeframes specified.
14. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or simultaneous participation in an investigational study involving no drug or device administration.
15. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
16. Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes